Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
SecuraBio clinical trials
The registry lists 25 studies whose lead sponsor is SecuraBio. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 20, 2026.
Keep track of what changes. Save the SecuraBio studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to SecuraBio.
- SecuraBio25 studiesSame company
Something wrong?
Focus areas
Conditions SecuraBio leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 25 of 25.
- A Study of Topical Duvelisib in Participants With Early-stage Mycosis FungoidesNot yet recruitingNCT07714187Phase 1
- A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeRecruitingNCT06522737Phase 3
- A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)CompletedNCT03372057Phase 2
- A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin LymphomaCompletedNCT04038359Phase 2
- Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular LymphomaTerminatedNCT02204982Phase 3
- A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)TerminatedNCT02391545Phase 1/2
- A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)CompletedNCT02004522Phase 3
- A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07CompletedNCT02049515Phase 3
- A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck CancerTerminatedNCT04193293Phase 1/2
- A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)CompletedNCT02711852Phase 2
- A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin LymphomaCompletedNCT01882803Phase 2
- Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic LymphomaWithdrawnNCT03370185Phase 2
- Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)TerminatedNCT02292225Phase 1
- A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic MalignanciesTerminatedNCT01476657Phase 1
- Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)WithdrawnNCT02605694Phase 2
- Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FLTerminatedNCT04342117
- IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction StudyCompletedNCT01549106Phase 1
- A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic SubjectsCompletedNCT01653756Phase 2
- Duvelisib in Hepatically Impaired Subjects Compared to Healthy SubjectsCompletedNCT02095587Phase 1
- A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate AloneCompletedNCT01851707Phase 2
- Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of MidazolamCompletedNCT01925911Phase 1
- IPI-145 ADME and Absolute Bioavailability StudyCompletedNCT01836861Phase 1
- Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145CompletedNCT02307461Phase 1
- Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145CompletedNCT01947777Phase 1
- A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)WithdrawnNCT02576275Phase 3